Autism Spectrum Disorder and Neonatal Serum Magnesium Levels in Preterm Infants

Area of Science:

• Neonatalogy
• Neurodevelopmental Disorders
• Perinatal Medicine

Background:

• Premature birth is a known risk factor for autism spectrum disorder (ASD).
• Maternal antenatal magnesium administration shows neuroprotective effects, reducing cerebral palsy risk in premature infants.
• This suggests a potential role for magnesium in mitigating neurodevelopmental risks in preterm infants.

Purpose of the Study:

• To investigate the association between neonatal magnesium levels and the risk of developing autism spectrum disorder in premature infants.
• To determine if magnesium has a protective effect against autism spectrum disorder in the preterm population.

Main Methods:

• A cohort study of 4855 preterm children was conducted.
• Neonatal magnesium levels were measured between 24 to 48 hours of life.
• Autism spectrum disorder status was determined subsequently, with statistical analysis to assess the association.

Main Results:

• No significant association was found between higher neonatal magnesium levels and a decreased risk of autism spectrum disorder (Adjusted Relative Risk: 1.15, 95% CI: 0.86-1.53).
• Magnesium levels varied by gestational age and maternal supplementation but were not associated with autism spectrum disorder status.
• The study did not find evidence supporting magnesium's protective role against autism spectrum disorder in premature infants.

Conclusions:

• Neonatal magnesium levels are not associated with reduced autism spectrum disorder risk in premature infants.
• The findings do not support magnesium as a preventative measure for autism spectrum disorder in this vulnerable population.
• Further research is essential to explore autism spectrum disorder etiology and potential interventions for premature infants.